Free Trial

Leap Therapeutics (LPTX) Stock Price, News & Analysis

-0.04 (-1.79%)
(As of 07/17/2024 ET)
Today's Range
50-Day Range
52-Week Range
60,795 shs
Average Volume
255,478 shs
Market Capitalization
$56.32 million
P/E Ratio
Dividend Yield
Price Target

Leap Therapeutics MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
372.7% Upside
$10.40 Price Target
Short Interest
3.57% of Float Sold Short
Dividend Strength
News Sentiment
1.61mentions of Leap Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
Proj. Earnings Growth
From ($1.66) to ($1.48) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.50 out of 5 stars

Medical Sector

277th out of 914 stocks

Pharmaceutical Preparations Industry

121st out of 433 stocks

LPTX stock logo

About Leap Therapeutics Stock (NASDAQ:LPTX)

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

LPTX Stock Price History

LPTX Stock News Headlines

I’m giving you the name of this investment for free
I want to help you achieve that right by accessing a new business model in America that has been unlocked by a billionaire who may end up sitting in Trump’s cabinet.
5 Best Biotech Penny Stocks to Invest In
I’m giving you the name of this investment for free
I want to help you achieve that right by accessing a new business model in America that has been unlocked by a billionaire who may end up sitting in Trump’s cabinet.
LPTX Apr 2024 5.000 call
LPTX Mar 2024 7.000 call
See More Headlines
Receive LPTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Leap Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
5 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$1.50 million
Book Value
$2.35 per share


Free Float
Market Cap
$55.30 million
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. Douglas E. Onsi J.D. (Age 55)
    CFO, General Counsel, Treasurer & Secretary, President, CEO & Director
    Comp: $1.1M
  • Mr. Augustine J. Lawlor (Age 67)
    Chief Operating Officer
    Comp: $749.81k
  • Dr. Cynthia A. Sirard M.D. (Age 54)
    Chief Medical Officer
    Comp: $747.57k
  • Dr. Jason S. Baum Ph.D. (Age 45)
    Chief Scientific Officer
  • Mr. Mark O'Mahony (Age 53)
    Chief Manufacturing Officer
  • Ms. Christine M. Granfield (Age 56)
    VP and Head of Regulatory Affairs & Quality

LPTX Stock Analysis - Frequently Asked Questions

How have LPTX shares performed this year?

Leap Therapeutics' stock was trading at $4.15 at the beginning of 2024. Since then, LPTX stock has decreased by 47.0% and is now trading at $2.20.
View the best growth stocks for 2024 here

How were Leap Therapeutics' earnings last quarter?

Leap Therapeutics, Inc. (NASDAQ:LPTX) released its earnings results on Monday, May, 13th. The company reported ($0.51) earnings per share for the quarter, beating the consensus estimate of ($0.57) by $0.06.

When did Leap Therapeutics' stock split?

Shares of Leap Therapeutics reverse split on the morning of Wednesday, June 21st 2023. The 1-10 reverse split was announced on Wednesday, June 21st 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, June 21st 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Who are Leap Therapeutics' major shareholders?

Leap Therapeutics' top institutional shareholders include Key Client Fiduciary Advisors LLC (1.11%).
View institutional ownership trends

How do I buy shares of Leap Therapeutics?

Shares of LPTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Leap Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Leap Therapeutics investors own include Allena Pharmaceuticals (ALNA), Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Amarin (AMRN), OPKO Health (OPK) and VYNE Therapeutics (VYNE).

This page (NASDAQ:LPTX) was last updated on 7/17/2024 by Staff

From Our Partners